ClinicalTrials.gg
CompletedNCT01977482Updated Jun 8, 2018Results posted

Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

A Phase 2 interventional study of GSK1278863 and Placebo in Anaemia, sponsored by GlaxoSmithKline. Completed at 107 sites in 16 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-06-08.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
9th of 30
216 · median 76
Started
2013
with 2 others
Phase 2
10 of 30
none open now
Registered
6th of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one is the 9th largest by enrollment, is one of 3 that started in 2013, is one of 10 in phase 2, and was the 6th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

This study is intended to evaluate the dose-response relationship of GSK1278863 over the first 4 weeks of treatment and evaluate the safety and efficacy of GSK1278863 over 24 weeks to maintain hemoglobin (Hgb) level in hemodialysis-dependent (HDD) subjects with anemia associated with chronic kidney disease (CKD) who are switched from a stable dose of recombinant human erythropoietin (rhEPO). The data generated will enable selection of the starting dose(s) and optimize dose adjustment regimen(s) for Phase 3 clinical trials.

03

Conditions studied

  • Anaemia

Keywords

  • hemoglobin
  • recombinant human erythropoietin
  • Chronic kidney disease
  • hemodialysis
  • pharmacokinetics
  • erythropoiesis stimulating agents
  • Anemia
  • GSK1278863
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Subjects are eligible if they meet all of the inclusion criteria below:
  • General criteria
  • Age: >=18 years of age. (Week -4 verification only)
  • Gender: Female and male subjects. (Week -4 verification only) Females: If of , must agree to use one of the approved methods, from Screening until completion of the Follow-up Visit OR of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, hysterectomy, or oophorectomy; or defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) 23.0-116.3 International units per liter (IU/L) and estradiol \<=10 picomole per liter (pmol/L) is confirmatory]. Females on hormone replacement therapy (HRT) whose menopausal status is in doubt will be required to use one of the approved contraception methods if they wish to continue their HRT during the study. Otherwise they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. For most forms of HRT, at least 2 weeks must elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method;
  • Q-T Interval Corrected for Heart Rate (): Bazett's Correction of QT Interval (QTcB) \<470 millisecond (msec) or QTcB \<480 msec in subjects with bundle branch block. There is no QTc inclusion criterion for a subject with a predominantly paced rhythm.
  • CKD-related criteria
  • Dialysis frequency: On hemodialysis (HD) three to five times weekly for at least 4 weeks prior to Week -4 Screening through Week 4. NOTE: Combination methods including hemofiltration (HF) or ultrafiltration (UF) with HD are allowed. However, the type of dialysis (HD, hemodiafiltration (HDF) or UF) should not change during the study.
  • Dialysis adequacy: A single-pool dialyzer clearance multiplied by dialyzer time divided by volume of distribution of urea (Kt/Vurea) of >=1.2 based on a historical value obtained within the prior month in order to ensure the adequacy of dialysis. If Kt/Vurea is not available, then an average of the last 2 values of urea reduction ratio (URR) of at least 65%. NOTE: Only needs confirming at Week -4.
  • : Baseline Hgb of 9.0-11.5 g/dL (may rescreen in a minimum of 2 weeks).
  • Stable rhEPO dose: Using the same rhEPO (epoetins or their biosimilars, or darbepoetin) with total weekly doses varying by no more than 50% during the 4 weeks prior to Week -4. At Day 1 (randomization), confirm that total weekly doses varied by no more than 50% during the screening period.
  • Iron replacement therapy: Subjects may be on stable maintenance oral or IV (\<=100 mg/week) iron supplementation. If subjects are on oral or IV iron, then doses must be stable for the 4 weeks prior to Week -4, during the screening phase, and through the first 4 weeks after Randomization.

Exclusion criteria

Exclusion Criteria:

  • Subjects are not eligible if they meet any of the exclusion criteria below:
  • CKD-related criteria
  • Dialysis modality: Planned change from HD to peritoneal dialysis within the study time period.
  • Renal transplant: Pre-emptive or scheduled renal transplant.
  • High rhEPO dose: An epoetin dose of >=360 IU/Kg/Week IV or >=250 IU/kg/week subcutaneous (SC) or darbepoetin dose of >=1.8 microgram (µg)/Kg/Week IV or SC within the prior 8 weeks through Day 1 (randomization).
  • Use of methoxy polyethylene glycol epoetin beta within the prior 8 weeks through Day 1 (randomization).
  • Laboratory test-based criteria (Week -4 verification only)
  • Vitamin B12: At or below the lower limit of the reference range (may rescreen in a minimum of 8 weeks).
  • Folate: \<2.0 nanogram (ng)/mL (\<4.5 nanomole (nmol)/L) (may rescreen in a minimum of 4 weeks).
  • Ferritin: \<100 ng/mL (\<100 Micrograms per liter).
  • Transferrin saturation (TSAT): Outside of the reference range.
  • Cardiovascular disease-related criteria
  • Myocardial infarction or acute coronary syndrome: Within the 8 weeks prior to Screening through Day 1 (randomization).
  • Stroke or : Within the 8 weeks prior to Week -4 Screening through Day 1 (randomization).
  • Heart failure: Class III/IV heart failure, as defined by the (NYHA) functional classification system diagnosed prior to Week -4 Screening through Day 1 (randomization); Symptomatic right heart failure diagnosed prior to Week -4 Screening through Day 1 (randomization).
  • Hypertension: Defined using pre-dialysis vitals (Week -4, Day 1) of diastolic blood pressure (DBP) >100 millimeters of mercury (mmHg) or systolic blood pressure (SBP) >170 mmHg.
  • Thrombotic disease: History of thrombotic disease (e.g., venous thrombosis such as deep vein thrombosis or pulmonary embolism, or arterial thrombosis such as new onset or worsening limb ischemia requiring intervention), except vascular access thrombosis, within the 8 weeks prior to Week -4 Screening through Day 1 (randomization).
  • Other disease-related criteria
  • Ophthalmology disease: Meeting any ophthalmologic-related exclusion criteria determined at the Screening ophthalmology exam.
  • Inflammatory disease: Active chronic inflammatory disease that could impact erythropoiesis (e.g., scleroderma, systemic lupus erythematosis, rheumatoid arthritis, celiac disease) diagnosed prior to Week -4 Screening through Day 1 (randomization).
  • Hematological disease: Any hematological disease including those affecting , white or red blood cells (e.g. sickle cell anemia, myelodysplastic syndromes, hematological , myeloma, hemolytic anemia and thalassemia), coagulation disorders (e.g., antiphospholipid syndrome, Protein C or S deficiency), or any other cause of anemia other than renal disease diagnosed prior to Week -4 Screening through Day 1 (randomization).
  • Liver disease: Current liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) or evidence at Screening of abnormal liver function tests [ (ALT) or aspartate transaminase (AST) > 2.0 x (ULN) or total > 1.5 x ULN]; or other hepatic abnormalities that in the opinion of the investigator would preclude the subject from participation in the study. NOTE: Those with or are eligible provided these exclusions are not met.
  • Major surgery: Major surgery (excluding vascular access surgery) within the prior 8 weeks, during the Week -4 Screening phase or planned during the study.
  • Transfusion: Blood transfusion within the prior 8 weeks, during the Week -4 Screening phase or an anticipated need for blood transfusion during the study.
  • GI Bleeding: Evidence of actively bleeding peptic, duodenal, or esophageal ulcer disease OR GI bleeding within the 8 weeks prior to Week -4 Screening through Day 1 (randomization).
  • Acute infection: Clinical evidence of acute infection or history of infection requiring intravenous (IV) antibiotic therapy within the 8 weeks prior to Week -4 Screening through Day 1 (randomization). NOTE: IV antibiotics as prophylaxis are allowed.
  • Malignancy: Subjects with a history of malignancy within the prior 5 years, who receiving treatment for cancer, or who have a strong family history of cancer (e.g., familial cancer disorders); with the exception of squamous cell or basal cell carcinoma of the skin that has been definitively treated prior to Week -4 Screening through Day 1 (randomization).
  • Concomitant medication and other Product-related criteria
  • Severe allergic reactions: History of severe allergic or anaphylactic reactions or to in the investigational product.
  • Drugs and supplements: Use of any prescription or non-prescription drugs or dietary supplements that are prohibited from Week -4 Screening until the Follow-up Visit.
  • Prior investigational product exposure: The Subject has participated in a clinical trial and has received an experimental investigational product within the prior 30 days from Week -4 Screening through Day 1 (randomization).
  • General health-related criteria
  • Other Conditions: Any other condition, clinical or laboratory abnormality, or examination finding that the Investigator considers would put the subject at unacceptable risk.
  • Pregnancy or Lactation: Pregnant females as determined by positive serum human chorionic gonadotropin (hCG) test OR women who are lactating at Week -4 Screening or during the trial.
  • Other Eligibility Criteria Considerations
  • Laboratory eligibility criteria will be assessed according to the central laboratory results for the screening samples.
  • Subjects who fail screening may be rescreened as soon as the investigator feels they may have become eligible. However, an individual subject may not rescreen more than twice. There is no predetermined amount of time that the investigator needs to wait to rescreen a previously ineligible subject, except those excluded for or folate who may only rescreen in 2 and 4 weeks, respectively, and those excluded for Vitamin B12 who may rescreen in 8 weeks
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    GSK1278863 4 mg

    Subjects will take GSK1278863 4 mg blinded once daily (OD) orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.

    Drug: GSK1278863

  • Experimental
    GSK1278863 6 mg

    Subjects will take GSK1278863 6 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.

    Drug: GSK1278863

  • Experimental
    GSK1278863 8 mg

    Subjects will take GSK1278863 8 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.

    Drug: GSK1278863

  • Experimental
    GSK1278863 10 mg

    Subjects will take GSK1278863 10 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.

    Drug: GSK1278863

  • Experimental
    GSK1278863 12 mg

    Subjects will take GSK1278863 12 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.

    Drug: GSK1278863

  • Active comparator
    Control

    Subjects will take GSK1278863 matching placebo blinded OD orally for 4 weeks with a glass of water. From Week 4, rhEPO will be administered and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.

    Drug: Placebo · Drug: rhEPO

Interventions

  • Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863

  • DrugPlacebo

    Matching placebo tablet for GSK1278863

  • DrugrhEPO

    rhEPO will be procured from local market

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin (Hgb) at Week 4

    Baseline Hgb value was the average of three Hgb values taken during screening period at Week (W) -4, W-2 and Day 1. Change from Baseline in Hgb was calculated as W4 value minus the Baseline value. To model the dose-response relationship a four-parameter Emax model was used. The dose response dataset was based on all non-missing data collected up to W4. Participants (par.) who had a Week 2 Hgb measurement, but a missing Week 4 Hgb measurement were included with a change from Baseline at Week 4 value imputed as twice the change from Baseline at Week 2. E0 is the expected Hgb change from Baseline for a par. receiving placebo and experiencing the average Hgb Baseline observed in the study. Emax is the expected Hgb change from Baseline for a par. receiving the highest dose above which no further increase in response can be achieved. ED50 is the dose that attains the intermediate response. Gamma is the slope parameter. Alpha is the coefficient of the model covariate for centred Baseline.

    Time frame: Baseline (Week -4, Week-2 and Day 1) and Week 4

Secondary outcomes

  1. Hgb Concentration at Week 24

    Hgb values measured at Week 24 are presented.

    Time frame: Week 24

  2. Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24

    The percentage of time in Hgb target range between Weeks 20 and 24 for a participant was calculated by dividing the total number of days that Hgb was within the target range (10.0 to 11.5 g/dL) while on treatment during Weeks 20 to 24 (using linear interpolation) by the total number of days the participant remained on treatment during the defined period. Similarly, percentage of time above Hgb target range and percentage of time below Hgb target range were calculated.

    Time frame: Week 20 to Week 24

  3. Number of Participants With Hgb in the Target Range at Week 24

    The number of participants with Hgb in the target range of 10.0 to 11.5 g/dL at Week 24 was recorded for each arm.

    Time frame: Week 24

  4. Number of Participants Reaching Pre-defined Hgb Stopping Criteria

    The number of participants who reached the Hgb stopping criteria of Hgb concentration \<7.5 g/dL were presented.

    Time frame: Up to 24 weeks

  5. Maximum Observed Change From Baseline in Erythropoietin (EPO)

    Blood samples for control arm were collected on Day 1 (pre-dose), Week 4 (5-15 minutes post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 5-15 minutes post-dose), Week 24 (pre-dose), and Week 28 (pre-dose) for EPO measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose), Week 4 (7-13, 8-14, 9-15, hours post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 3 hour post-dose) Week 24 (pre-dose), and Week 28 (pre-dose) for EPO measurement. The maximum observed change from baseline in EPO was recorded for each arm. Baseline value for EPO is the pre-dose value on Day 1. Change from Baseline in EPO was calculated as the individual post-dose values minus the Baseline value.

    Time frame: Baseline (Day 1) to Week 28

  6. Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)

    Blood samples for control arm were collected on Day 1 (pre-dose), Week 4 (5-15 minutes post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 5-15 minutes post-dose), Week 24 (pre-dose), and Week 28 (pre-dose) for VEGF measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose), Week 4 (7-13, 8-14, 9-15, hours post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 3 hour post-dose) Week 24 (pre-dose), and Week 28 (pre-dose) for VEGF measurement. The maximum observed percent change from Baseline in VEGF was recorded for each arm. Baseline value for VEGF is the pre-dose value on Day 1. Percent change from Baseline was calculated as 100 multiplied by exponential of mean change in log scale minus 1.

    Time frame: Baseline (Day 1) to Week 28

  7. Population Plasma PK Parameters of GSK1278863 and Metabolites

    Blood samples were collected for individual plasma GSK1278863and metabolite (GSK2391220, GSK2499166, GSK2531403, GSK2531400, GSK2531399, and GSK2531398) concentrations measurement on Day (D) 1 (pre-dose \[PrD), at Week (W) 4 (6-12, 7-13, 8-14, and 9-15 hour \[hr\] post-dose \[PoD), and at W20 (PrD, 1, 2, and 3 hour PoD). Pharmacokinetic population: All participants from whom a PK sample has been obtained and analyzed.

    Time frame: Day 1, Week 4, and Week 20

  8. Percent Change From Baseline in Hepcidin at Week 24

    Hepcidin is a regulator of iron metabolism. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change from Baseline was calculated as 100 multiplied by exponential of mean change in log scale minus 1.

    Time frame: Baseline (Day 1) and Week 24

  9. Change From Baseline in Ferritin at Week 24

    Baseline value for ferritin is the pre-dose value on Day 1. Change from Baseline in ferritin was calculated as the Week 24 value minus the Baseline value.

    Time frame: Baseline (Day 1) and Week 24

  10. Change From Baseline in Transferrin at Week 24

    Baseline value for transferrin is the pre-dose value on Day 1. Change from Baseline in transferrin was calculated as the Week 24 value minus the Baseline value.

    Time frame: Baseline (Day 1) and Week 24

  11. Percent Change From Baseline in Transferrin Saturation at Week 24

    Transferrin saturation is measured as a percentage, it is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change from Baseline =: 100\*(exp(Mean change log scale)-1).

    Time frame: Baseline (Day 1) and Week 24

  12. Change From Baseline in Total Iron at Week 24

    Baseline value for total iron is the pre-dose value on Day 1. Change from Baseline in total iron was calculated as the Week 24 value minus the Baseline value.

    Time frame: Baseline (Day 1) and Week 24

  13. Change From Baseline in Total Iron Binding Capacity at Week 24

    Total iron-binding capacity is a medical laboratory test that measures the blood's capacity to bind iron with transferrin. Baseline value for total iron binding capacity is the pre-dose value on Day 1. Change from Baseline in total iron binding capacity was calculated as the Week 24 value minus the Baseline value.

    Time frame: Baseline (Day 1) and Week 24

  14. Change From Baseline in Reticulocyte Hemoglobin at Week 24

    Baseline value for reticulocyte hemoglobin is the pre-dose value on Day 1. Change from Baseline in reticulocyte hemoglobin was calculated as the Week 24 value minus the Baseline value.

    Time frame: Baseline (Day 1) and Week 24

  15. Change From Baseline in Hematocrit at Week 24

    Hematocrit is the ratio of the volume of red blood cells to the total volume of blood. Baseline value for hematocrit is the pre-dose value on Day 1. Change from Baseline in hematocrit was calculated as the Week 24 value minus the Baseline value.

    Time frame: Baseline (Day 1) and Week 24

  16. Change From Baseline in Red Blood Cells at Week 24

    Baseline value for red blood cells is the pre-dose value on Day 1. Change from Baseline in red blood cells was calculated as the Week 24 value minus the Baseline value.

    Time frame: Baseline (Day 1) and Week 24

  17. Change From Baseline in Reticulocyte Count at Week 24

    A reticulocyte count is a blood test that measures the percentage of reticulocytes in the blood. Reticulocytes are slightly immature red blood cells. Baseline value for reticulocyte count is the pre-dose value on Day 1. Change from Baseline in reticulocyte count was calculated as the Week 24 value minus the Baseline value.

    Time frame: Baseline (Day 1) and Week 24

07

Results

Posted Feb 14, 2017

Participant flow

Eligible participants were hemodialysis-dependent with anemia associated with chronic kidney disease who were switched from a stable dose of recombinant human erythropoietin (rhEPO).

Participant flow — Overall Study
MilestoneControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Started393940394019
Completed363035353714
Not completed395435
Withdrew: Adverse event011020
Withdrew: Lost to follow-up100000
Withdrew: Physician decision010000
Withdrew: Protocol violation001000
Withdrew: Other-protocol-defined stopping criteria032100
Withdrew: Withdrawal by subject241315

Outcome measures

PrimaryChange From Baseline in Hemoglobin (Hgb) at Week 4

Baseline Hgb value was the average of three Hgb values taken during screening period at Week (W) -4, W-2 and Day 1. Change from Baseline in Hgb was calculated as W4 value minus the Baseline value. To model the dose-response relationship a four-parameter Emax model was used. The dose response dataset was based on all non-missing data collected up to W4. Participants (par.) who had a Week 2 Hgb measurement, but a missing Week 4 Hgb measurement were included with a change from Baseline at Week 4 value imputed as twice the change from Baseline at Week 2. E0 is the expected Hgb change from Baseline for a par. receiving placebo and experiencing the average Hgb Baseline observed in the study. Emax is the expected Hgb change from Baseline for a par. receiving the highest dose above which no further increase in response can be achieved. ED50 is the dose that attains the intermediate response. Gamma is the slope parameter. Alpha is the coefficient of the model covariate for centred Baseline.

Time frame:
Baseline (Week -4, Week-2 and Day 1) and Week 4
Reported as:
Mean · grams (g)/deciliter (dL)
Change From Baseline in Hemoglobin (Hgb) at Week 4
grams (g)/deciliter (dL)ControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Change From Baseline in Hemoglobin (Hgb) at Week 4-0.64 ± 0.829-0.24 ± 0.9890.08 ± 1.1310.42 ± 0.7960.64 ± 1.1770.61 ± 1.245
Statistical analysis
  • Control vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg vs GSK1278863 12 mg · E0 (g/dl): -0.664 · 95% CI -0.960 to -0.387Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Control vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg vs GSK1278863 12 mg · Ed50 (milligrams[mg]): 33.531 · 95% CI 15.566 to 48.948Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Control vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg vs GSK1278863 12 mg · Emax (g/dl): 5.234 · 95% CI 2.691 to 7.940Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Control vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg vs GSK1278863 12 mg · Gamma: 1.145 · 95% CI 0.748 to 1.738Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Control vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg vs GSK1278863 12 mg · Var: 1.012 · 95% CI 0.840 to 1.234Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Control vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg vs GSK1278863 12 mg · Alpha: -0.206 · 95% CI -0.397 to -0.014Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Control vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg vs GSK1278863 12 mg · Minimally effective dose (med) (mg): 0.418 · 95% CI 0.000 to 2.342Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Control vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg vs GSK1278863 12 mg · Dose that achieves a change of -0.25g/dl: 2.423 · 95% CI 0.000 to 4.150Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Control vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg vs GSK1278863 12 mg · Target dose (td) (mg): 4.406 · 95% CI 2.544 to 5.995Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Control vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg vs GSK1278863 12 mg · Dose that achieves a change of 0.25 g/dl: 6.430 · 95% CI 4.698 to 8.010Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Control vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg vs GSK1278863 12 mg · Dose that achieves a change of 0.5 g/dl: 8.542 · 95% CI 6.931 to 10.523Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Control vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg vs GSK1278863 12 mg · Dose that achieves a change of 0.75 g/dl: 10.800 · 95% CI 9.024 to 14.004Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Control vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg vs GSK1278863 12 mg · Dose that achieves a change of 1 g/dl: 13.248 · 95% CI 10.891 to 18.916Posterior median and 95% credibility intervals were estimated using Bayesian methods.
SecondaryHgb Concentration at Week 24

Hgb values measured at Week 24 are presented.

Time frame:
Week 24
Reported as:
Mean · g/dL
Hgb Concentration at Week 24
g/dLControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Hgb Concentration at Week 2410.56 ± 0.97410.29 ± 0.86410.54 ± 1.01010.63 ± 1.09910.28 ± 0.85610.70 ± 0.867
SecondaryPercentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24

The percentage of time in Hgb target range between Weeks 20 and 24 for a participant was calculated by dividing the total number of days that Hgb was within the target range (10.0 to 11.5 g/dL) while on treatment during Weeks 20 to 24 (using linear interpolation) by the total number of days the participant remained on treatment during the defined period. Similarly, percentage of time above Hgb target range and percentage of time below Hgb target range were calculated.

Time frame:
Week 20 to Week 24
Reported as:
Mean · Percentage of days
Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24
Percentage of daysControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Percentage of time within target range54.59 ± 42.04474.77 ± 38.79757.38 ± 40.50537.46 ± 41.77548.97 ± 42.49055.23 ± 40.350
Percentage of time above target range24.65 ± 38.5566.89 ± 22.13717.18 ± 30.44633.15 ± 42.85618.27 ± 33.69826.88 ± 36.154
Percentage of time below target range20.76 ± 36.58718.34 ± 35.77825.44 ± 40.12029.39 ± 42.67032.76 ± 43.78017.89 ± 36.836
SecondaryNumber of Participants With Hgb in the Target Range at Week 24

The number of participants with Hgb in the target range of 10.0 to 11.5 g/dL at Week 24 was recorded for each arm.

Time frame:
Week 24
Reported as:
Number · Participants
Number of Participants With Hgb in the Target Range at Week 24
ParticipantsControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Number of Participants With Hgb in the Target Range at Week 2414131610158
SecondaryNumber of Participants Reaching Pre-defined Hgb Stopping Criteria

The number of participants who reached the Hgb stopping criteria of Hgb concentration \<7.5 g/dL were presented.

Time frame:
Up to 24 weeks
Reported as:
Number · Participants
Number of Participants Reaching Pre-defined Hgb Stopping Criteria
ParticipantsControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Number of Participants Reaching Pre-defined Hgb Stopping Criteria000000
SecondaryMaximum Observed Change From Baseline in Erythropoietin (EPO)

Blood samples for control arm were collected on Day 1 (pre-dose), Week 4 (5-15 minutes post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 5-15 minutes post-dose), Week 24 (pre-dose), and Week 28 (pre-dose) for EPO measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose), Week 4 (7-13, 8-14, 9-15, hours post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 3 hour post-dose) Week 24 (pre-dose), and Week 28 (pre-dose) for EPO measurement. The maximum observed change from baseline in EPO was recorded for each arm. Baseline value for EPO is the pre-dose value on Day 1. Change from Baseline in EPO was calculated as the individual post-dose values minus the Baseline value.

Time frame:
Baseline (Day 1) to Week 28
Reported as:
Mean · international units(IU)/Liter (L)
Maximum Observed Change From Baseline in Erythropoietin (EPO)
international units(IU)/Liter (L)ControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Maximum Observed Change From Baseline in Erythropoietin (EPO)1946.45 ± 8456.31348.86 ± 117.05036.63 ± 35.48584.53 ± 225.76882.00 ± 99.66024.63 ± 235.820
SecondaryMaximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)

Blood samples for control arm were collected on Day 1 (pre-dose), Week 4 (5-15 minutes post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 5-15 minutes post-dose), Week 24 (pre-dose), and Week 28 (pre-dose) for VEGF measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose), Week 4 (7-13, 8-14, 9-15, hours post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 3 hour post-dose) Week 24 (pre-dose), and Week 28 (pre-dose) for VEGF measurement. The maximum observed percent change from Baseline in VEGF was recorded for each arm. Baseline value for VEGF is the pre-dose value on Day 1. Percent change from Baseline was calculated as 100 multiplied by exponential of mean change in log scale minus 1.

Time frame:
Baseline (Day 1) to Week 28
Reported as:
Geometric mean · Percent change
Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)
Percent changeControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)36.02 (16.45 to 58.87)36.92 (19.33 to 57.11)41.73 (22.65 to 63.77)54.91 (37.38 to 74.69)50.65 (31.88 to 72.10)50.97 (21.49 to 87.60)
SecondaryPopulation Plasma PK Parameters of GSK1278863 and Metabolites

Blood samples were collected for individual plasma GSK1278863and metabolite (GSK2391220, GSK2499166, GSK2531403, GSK2531400, GSK2531399, and GSK2531398) concentrations measurement on Day (D) 1 (pre-dose \[PrD), at Week (W) 4 (6-12, 7-13, 8-14, and 9-15 hour \[hr\] post-dose \[PoD), and at W20 (PrD, 1, 2, and 3 hour PoD). Pharmacokinetic population: All participants from whom a PK sample has been obtained and analyzed.

Time frame:
Day 1, Week 4, and Week 20
Reported as:
Mean · nanograms (ng)/milliliter (mL)
Population Plasma PK Parameters of GSK1278863 and Metabolites
nanograms (ng)/milliliter (mL)GSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
GSK1278863, D1, PrD, n=39, 40, 39, 40, 180.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
GSK1278863, W4, 6-12 hr PoD, n=36, 37, 37, 35, 156.3 ± 10.049.3 ± 19.067.7 ± 18.4625.4 ± 53.379.0 ± 18.80
GSK1278863, W4, 7-13 hr PoD, n=36, 37, 35, 35, 1510.6 ± 25.1516.3 ± 57.248.7 ± 19.8519.9 ± 42.658.0 ± 16.92
GSK1278863, W4, 8-14 hr PoD, n=35, 37, 36, 35, 157.5 ± 16.808.1 ± 23.765.6 ± 11.7512.7 ± 28.604.6 ± 6.87
GSK1278863, W4, 9-15 hr PoD, n=35, 36, 36, 35, 156.8 ± 14.534.6 ± 10.494.4 ± 9.1911.3 ± 25.3611.2 ± 33.59
GSK1278863, W20, PrD, n=23, 28, 27, 23, 142.3 ± 6.440.7 ± 2.550.9 ± 2.827.9 ± 30.996.6 ± 20.22
GSK1278863, W20, 1 hr PoD, n=23, 27, 27, 24, 1325.9 ± 35.7437.6 ± 53.7788.2 ± 153.0658.5 ± 85.9165.2 ± 127.21
GSK1278863, W20, 2 hr PoD, n=23, 27, 27, 24, 1334.2 ± 31.7652.4 ± 53.3262.8 ± 85.3782.7 ± 117.9763.3 ± 102.15
GSK1278863, W20, 3 hr PoD, n=23, 27, 27, 24, 1443.6 ± 58.3639.2 ± 44.5944.1 ± 70.5371.2 ± 110.9165.8 ± 100.80
GSK2391220, D1, PrD, n=39, 40, 39, 40, 180.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
GSK2391220, W4, 6-12 hr PoD, n=36, 37, 37, 35, 159.1 ± 6.6812.9 ± 8.3218.5 ± 13.7220.1 ± 12.3221.3 ± 17.34
GSK2391220, W4, 7-13 hr PoD, n=36, 37, 35, 35, 155.1 ± 4.226.7 ± 5.5110.3 ± 8.5510.9 ± 6.3713.1 ± 12.44
GSK2391220, W4, 8-14 hr PoD, n=35, 37, 36, 35, 153.8 ± 3.664.5 ± 4.167.4 ± 6.447.4 ± 4.517.2 ± 6.97
GSK2391220, W4, 9-15 hr PoD, n=35, 36, 36, 35, 153.3 ± 3.763.3 ± 3.155.3 ± 4.865.4 ± 3.636.6 ± 5.72
GSK2391220, W20, PrD, n=23, 28, 27, 23, 145.0 ± 7.723.2 ± 4.974.1 ± 5.844.6 ± 9.293.5 ± 6.69
GSK2391220, W20, 1 hr PoD, n=23, 27, 27, 24, 133.9 ± 5.592.7 ± 3.604.3 ± 4.905.0 ± 8.102.6 ± 3.64
GSK2391220, W20, 2 hr PoD, n=23, 27, 27, 24, 135.4 ± 5.584.5 ± 4.966.5 ± 6.938.1 ± 10.334.9 ± 4.08
GSK2391220, W20, 3 hr PoD, n=23, 27, 27, 24, 145.3 ± 4.645.0 ± 5.267.3 ± 6.698.2 ± 6.526.1 ± 4.92
GSK2487818, D1, PrD, n=39, 40, 39, 40, 180.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
GSK2487818, W4, 6-12 hr PoD, n=36, 37, 37, 35, 153.1 ± 2.824.1 ± 4.475.7 ± 6.317.2 ± 6.575.2 ± 4.66
GSK2487818, W4, 7-13 hr PoD, n=36, 37, 35, 35, 151.8 ± 1.752.6 ± 3.813.5 ± 4.554.1 ± 3.733.7 ± 4.61
GSK2487818, W4, 8-14 hr PoD, n=35, 37, 36, 35, 151.5 ± 1.671.9 ± 3.212.7 ± 3.582.7 ± 2.441.7 ± 1.68
GSK2487818, W4, 9-15 hr PoD, n=35, 36, 36, 35, 151.4 ± 1.881.5 ± 2.461.9 ± 2.851.9 ± 1.921.9 ± 2.21
GSK2487818, W20, PrD, n=23, 28, 27, 23, 141.2 ± 3.380.5 ± 1.050.7 ± 1.281.3 ± 4.090.7 ± 1.84
GSK2487818, W20, 1 hr PoD, n=23, 27, 27, 24, 132.0 ± 3.821.3 ± 1.732.7 ± 3.973.4 ± 5.881.0 ± 1.34
GSK2487818, W20, 2 hr PoD, n=23, 27, 27, 24, 133.8 ± 4.583.6 ± 4.365.0 ± 5.826.3 ± 8.043.7 ± 3.28
GSK2487818, W20, 3 hr PoD, n=23, 27, 27, 24, 143.9 ± 3.494.3 ± 4.765.7 ± 5.286.5 ± 5.055.0 ± 4.43
GSK2506102, D1, PrD, n=39, 40, 39, 40, 180.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
GSK2506102, W4, 6-12 hr PoD, n=36, 37, 37, 35, 153.2 ± 1.984.9 ± 2.686.6 ± 4.167.6 ± 4.309.0 ± 6.19
GSK2506102, W4, 7-13 hr PoD, n=36, 37, 35, 35, 151.8 ± 1.312.5 ± 1.713.7 ± 2.604.1 ± 2.155.4 ± 4.10
GSK2506102, W4, 8-14 hr PoD, n=35, 37, 36, 35, 151.3 ± 1.071.6 ± 1.162.6 ± 1.942.9 ± 1.682.9 ± 2.24
GSK2506102, W4, 9-15 hr PoD, n=35, 36, 36, 35, 151.1 ± 1.161.2 ± 0.881.9 ± 1.522.1 ± 1.232.7 ± 2.04
GSK2506102, W20, PrD, n=23, 28, 27, 23, 142.3 ± 1.991.9 ± 2.052.3 ± 2.092.6 ± 2.872.2 ± 2.87
GSK2506102, W20, 1 hr PoD, n=23, 27, 27, 24, 131.4 ± 1.271.1 ± 1.401.4 ± 1.221.8 ± 2.121.4 ± 1.57
GSK2506102, W20, 2 hr PoD, n=23, 27, 27, 24, 131.5 ± 1.251.2 ± 1.241.8 ± 1.722.2 ± 2.531.6 ± 1.37
GSK2506102, W20, 3 hr PoD, n=23, 27, 27, 24, 141.4 ± 1.121.3 ± 1.261.9 ± 1.532.1 ± 1.661.7 ± 1.42
GSK2531398, D1, PrD, n=39, 40, 39, 40, 180.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
GSK2531398, W4, 6-12 hr PoD, n=36, 37, 37, 35, 153.4 ± 2.464.9 ± 3.116.9 ± 4.528.0 ± 4.877.9 ± 5.75
GSK2531398, W4, 7-13 hr PoD, n=36, 37, 35, 35, 152.0 ± 1.722.7 ± 2.414.0 ± 2.974.5 ± 2.704.9 ± 4.05
GSK2531398, W4, 8-14 hr PoD, n=35, 37, 36, 35, 151.5 ± 1.461.8 ± 1.862.9 ± 2.303.1 ± 1.952.5 ± 1.78
GSK2531398, W4, 9-15 hr PoD, n=35, 36, 36, 35, 151.4 ± 1.581.4 ± 1.492.1 ± 1.992.2 ± 1.382.3 ± 1.42
GSK2531398, W20, PrD, n=23, 28, 27, 23, 141.5 ± 2.311.2 ± 2.031.4 ± 1.931.6 ± 3.801.2 ± 2.67
GSK2531398, W20, 1 hr PoD, n=23, 27, 27, 24, 131.3 ± 1.891.0 ± 1.341.6 ± 1.812.0 ± 3.581.0 ± 1.45
GSK2531398, W20, 2 hr PoD, n=23, 27, 27, 24, 132.1 ± 2.241.9 ± 2.092.9 ± 3.283.5 ± 4.692.1 ± 1.79
GSK2531398, W20, 3 hr PoD, n=23, 27, 27, 24, 142.3 ± 2.042.2 ± 2.223.3 ± 2.893.8 ± 3.102.8 ± 2.34
GSK2531401, D1, PrD, n=39, 40, 39, 40, 180.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.02
GSK2531401, W4, 6-12 hr PoD, n=36, 37, 37, 35, 159.9 ± 8.0014.7 ± 10.0222.2 ± 14.7124.5 ± 18.2729.1 ± 24.55
GSK2531401, W4, 7-13 hr PoD, n=36, 37, 35, 35, 155.4 ± 4.497.1 ± 5.5311.8 ± 8.4913.1 ± 9.5017.3 ± 16.03
GSK2531401, W4, 8-14 hr PoD, n=35, 37, 36, 35, 154.0 ± 3.634.5 ± 3.508.1 ± 5.749.0 ± 7.0510.1 ± 10.61
GSK2531401, W4, 9-15 hr PoD, n=35, 36, 36, 35, 153.3 ± 3.363.2 ± 2.355.9 ± 4.666.3 ± 4.908.7 ± 8.72
GSK2531401, W20, PrD, n=23, 28, 27, 23, 147.7 ± 7.717.3 ± 7.347.9 ± 7.379.3 ± 10.957.2 ± 10.04
GSK2531401, W20, 1 hr PoD, n=23, 27, 27, 24, 134.2 ± 4.524.0 ± 6.774.7 ± 4.185.6 ± 7.484.5 ± 5.44
GSK2531401, W20, 2 hr PoD, n=23, 27, 27, 24, 134.2 ± 4.443.6 ± 4.504.8 ± 4.086.1 ± 8.214.4 ± 4.41
GSK2531401, W20, 3 hr PoD, n=23, 27, 27, 24, 144.1 ± 4.073.6 ± 4.555.0 ± 4.645.5 ± 5.384.5 ± 4.28
GSK2531403, D1, PrD, n=39, 40, 39, 40, 180.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
GSK2531403, W4, 6-12 hr PoD, n=36, 37, 37, 35, 1511.4 ± 7.4717.0 ± 9.8923.1 ± 15.2225.4 ± 14.2528.8 ± 21.46
GSK2531403, W4, 7-13 hr PoD, n=36, 37, 35, 35, 156.3 ± 4.848.6 ± 6.4313.1 ± 9.7313.9 ± 7.6617.4 ± 14.72
GSK2531403, W4, 8-14 hr PoD, n=35, 37, 36, 35, 154.7 ± 4.235.7 ± 4.639.3 ± 7.379.6 ± 5.509.9 ± 9.05
GSK2531403, W4, 9-15 hr PoD, n=35, 36, 36, 35, 154.1 ± 4.604.1 ± 3.416.7 ± 5.506.9 ± 4.258.9 ± 7.79
GSK2531403, W20, PrD, n=23, 28, 27, 23, 147.8 ± 8.536.0 ± 8.086.7 ± 6.747.8 ± 11.146.2 ± 8.78
GSK2531403, W20, 1 hr PoD, n=23, 27, 27, 24, 134.9 ± 5.563.8 ± 4.885.0 ± 4.716.2 ± 8.654.0 ± 4.80
GSK2531403, W20, 2 hr PoD, n=23, 27, 27, 24, 135.7 ± 5.434.7 ± 4.916.8 ± 6.548.5 ± 10.835.5 ± 4.58
GSK2531403, W20, 3 hr PoD, n=23, 27, 27, 24, 145.5 ± 4.525.1 ± 5.187.4 ± 6.438.4 ± 6.866.5 ± 5.14
SecondaryPercent Change From Baseline in Hepcidin at Week 24

Hepcidin is a regulator of iron metabolism. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change from Baseline was calculated as 100 multiplied by exponential of mean change in log scale minus 1.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Geometric mean · Percent change
Percent Change From Baseline in Hepcidin at Week 24
Percent changeControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Percent Change From Baseline in Hepcidin at Week 243.63 (-20.39 to 34.89)-17.39 (-42.36 to 18.40)-11.85 (-26.47 to 5.67)-30.28 (-48.08 to -6.37)-6.91 (-28.69 to 21.52)-42.13 (-62.82 to -9.95)
SecondaryChange From Baseline in Ferritin at Week 24

Baseline value for ferritin is the pre-dose value on Day 1. Change from Baseline in ferritin was calculated as the Week 24 value minus the Baseline value.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · Micrograms/Liter
Change From Baseline in Ferritin at Week 24
Micrograms/LiterControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Change From Baseline in Ferritin at Week 2456.8 ± 214.27-29.4 ± 357.10-50.4 ± 408.99-95.6 ± 304.61-20.2 ± 227.34-125.2 ± 354.64
SecondaryChange From Baseline in Transferrin at Week 24

Baseline value for transferrin is the pre-dose value on Day 1. Change from Baseline in transferrin was calculated as the Week 24 value minus the Baseline value.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · grams (g)/Liter (L)
Change From Baseline in Transferrin at Week 24
grams (g)/Liter (L)ControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Change From Baseline in Transferrin at Week 24-0.133 ± 0.29030.238 ± 0.37090.198 ± 0.28910.226 ± 0.27060.249 ± 0.32130.393 ± 0.3165
SecondaryPercent Change From Baseline in Transferrin Saturation at Week 24

Transferrin saturation is measured as a percentage, it is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change from Baseline =: 100\*(exp(Mean change log scale)-1).

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Geometric mean · Percent change
Percent Change From Baseline in Transferrin Saturation at Week 24
Percent changeControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Percent Change From Baseline in Transferrin Saturation at Week 24-9.0 (-27.3 to 13.9)-3.7 (-22.9 to 20.4)-12.1 (-23.4 to 0.9)-8.3 (-22.9 to 9.0)8.2 (-7.7 to 26.8)-2.5 (-16.0 to 13.2)
SecondaryChange From Baseline in Total Iron at Week 24

Baseline value for total iron is the pre-dose value on Day 1. Change from Baseline in total iron was calculated as the Week 24 value minus the Baseline value.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · Micromoles/Liter
Change From Baseline in Total Iron at Week 24
Micromoles/LiterControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Change From Baseline in Total Iron at Week 24-0.8 ± 7.640.9 ± 9.750.3 ± 5.200.2 ± 6.512.0 ± 3.961.6 ± 3.18
SecondaryChange From Baseline in Total Iron Binding Capacity at Week 24

Total iron-binding capacity is a medical laboratory test that measures the blood's capacity to bind iron with transferrin. Baseline value for total iron binding capacity is the pre-dose value on Day 1. Change from Baseline in total iron binding capacity was calculated as the Week 24 value minus the Baseline value.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · Micromoles/Liter
Change From Baseline in Total Iron Binding Capacity at Week 24
Micromoles/LiterControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Change From Baseline in Total Iron Binding Capacity at Week 24-2.0 ± 4.486.0 ± 7.934.2 ± 6.796.6 ± 5.754.8 ± 6.256.2 ± 6.44
SecondaryChange From Baseline in Reticulocyte Hemoglobin at Week 24

Baseline value for reticulocyte hemoglobin is the pre-dose value on Day 1. Change from Baseline in reticulocyte hemoglobin was calculated as the Week 24 value minus the Baseline value.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · Picogram
Change From Baseline in Reticulocyte Hemoglobin at Week 24
PicogramControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Change From Baseline in Reticulocyte Hemoglobin at Week 24-0.19 ± 1.610-0.28 ± 1.948-0.62 ± 2.046-0.42 ± 1.458-0.51 ± 1.377-0.63 ± 1.119
SecondaryChange From Baseline in Hematocrit at Week 24

Hematocrit is the ratio of the volume of red blood cells to the total volume of blood. Baseline value for hematocrit is the pre-dose value on Day 1. Change from Baseline in hematocrit was calculated as the Week 24 value minus the Baseline value.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · Ratio
Change From Baseline in Hematocrit at Week 24
RatioControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Change From Baseline in Hematocrit at Week 24-0.0028 ± 0.04358-0.0096 ± 0.040730.0020 ± 0.035790.0043 ± 0.04254-0.0021 ± 0.026780.0108 ± 0.03557
SecondaryChange From Baseline in Red Blood Cells at Week 24

Baseline value for red blood cells is the pre-dose value on Day 1. Change from Baseline in red blood cells was calculated as the Week 24 value minus the Baseline value.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · 10^12 cells/Liter
Change From Baseline in Red Blood Cells at Week 24
10^12 cells/LiterControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Change From Baseline in Red Blood Cells at Week 240.01 ± 0.460-0.06 ± 0.3960.04 ± 0.3740.07 ± 0.3990.03 ± 0.3000.17 ± 0.366
SecondaryChange From Baseline in Reticulocyte Count at Week 24

A reticulocyte count is a blood test that measures the percentage of reticulocytes in the blood. Reticulocytes are slightly immature red blood cells. Baseline value for reticulocyte count is the pre-dose value on Day 1. Change from Baseline in reticulocyte count was calculated as the Week 24 value minus the Baseline value.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · Percentage of reticulocytes in blood
Change From Baseline in Reticulocyte Count at Week 24
Percentage of reticulocytes in bloodControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Change From Baseline in Reticulocyte Count at Week 240.40 ± 0.6630.16 ± 1.1620.18 ± 0.5710.03 ± 0.684-0.15 ± 0.8380.10 ± 0.527

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study treatment and until the follow up contact (up to 28 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control—11/39 (28.2%)17/39 (43.6%)
GSK1278863 4 mg—10/39 (25.6%)28/39 (71.8%)
GSK1278863 6 mg—8/40 (20%)17/40 (42.5%)
GSK1278863 8 mg—8/39 (20.5%)25/39 (64.1%)
GSK1278863 10 mg—11/40 (27.5%)21/40 (52.5%)
GSK1278863 12 mg—1/19 (5.3%)6/19 (31.6%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
Device related sepsisInfections and infestations0/390/390/400/390/401/19
Cardiac arrestCardiac disorders0/392/390/400/391/400/19
GastroenteritisInfections and infestations0/391/390/402/390/400/19
Acute myocardial infarctionCardiac disorders0/391/391/400/391/400/19
Angina pectorisCardiac disorders0/391/390/400/391/400/19
Angina unstableCardiac disorders0/391/390/400/391/400/19
Atrioventricular blockCardiac disorders1/390/390/400/390/400/19
Cardiac failureCardiac disorders0/390/391/401/390/400/19
Cardiac failure acuteCardiac disorders0/391/390/400/390/400/19
Sick sinus syndromeCardiac disorders1/390/390/400/390/400/19
Most frequent other events
Showing 10 of 50
Most frequent other events
EventControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mg
DiarrhoeaGastrointestinal disorders2/395/392/407/392/401/19
NauseaGastrointestinal disorders0/396/393/402/391/401/19
HypertensionVascular disorders1/396/390/402/394/400/19
NasopharyngitisInfections and infestations5/395/396/403/394/401/19
Abdominal painGastrointestinal disorders0/394/390/401/390/400/19
HyperkalaemiaMetabolism and nutrition disorders0/392/391/404/391/400/19
Back painMusculoskeletal and connective tissue disorders4/390/392/401/394/400/19
HeadacheNervous system disorders2/394/391/402/392/400/19
VomitingGastrointestinal disorders1/393/392/401/392/400/19
Pain in extremityMusculoskeletal and connective tissue disorders0/390/390/403/391/400/19

Baseline characteristics

Age, Continuous
Age, Continuous(Years)ControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mgTotal
Years59.7 ± 18.7458.7 ± 13.3363.5 ± 14.0060.1 ± 10.3655.4 ± 15.5059.9 ± 13.2659.5 ± 14.58
Sex: Female, Male
Sex: Female, Male(Participants)ControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mgTotal
Female1315121517880
Male262428242311136
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ControlGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgGSK1278863 12 mgTotal
White232828283112150
African American74534427
Asian76775335
Other2101004
08

Study locations

107 sites
  • GSK Investigational Site
    Azusa, California 91702, United States
  • GSK Investigational Site
    Los Angeles, California 90022, United States
  • GSK Investigational Site
    Los Angeles, California 90025, United States
  • GSK Investigational Site
    San Dimas, California 91773, United States
  • GSK Investigational Site
    West Hills, California 91307, United States
  • GSK Investigational Site
    Lauderdale Lakes, Florida 33313, United States
  • GSK Investigational Site
    Pembroke Pines, Florida 33028, United States
  • GSK Investigational Site
    Macon, Georgia 31217, United States
  • GSK Investigational Site
    Evergreen Park, Illinois 60805, United States
  • GSK Investigational Site
    Bethesda, Maryland 20814, United States
  • GSK Investigational Site
    Farmington, Missouri 63640, United States
  • GSK Investigational Site
    Amherst, New York 14226, United States
  • GSK Investigational Site
    Bronx, New York 10461, United States
  • GSK Investigational Site
    Charlotte, North Carolina, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37923, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Temple, Texas 76502, United States
  • GSK Investigational Site
    Liverpool, New South Wales 2170, Australia
  • GSK Investigational Site
    Westmead, New South Wales 2145, Australia
  • GSK Investigational Site
    Woolloongabba, Queensland 4102, Australia
  • GSK Investigational Site
    Adelaide, South Australia 5000, Australia
  • GSK Investigational Site
    Nedlands, Western Australia 6009, Australia
  • GSK Investigational Site
    Calgary, Alberta T2R 0X7, Canada
  • GSK Investigational Site
    Edmonton, Alberta T6G 2B7, Canada
  • GSK Investigational Site
    Kitchener, Ontario N2G 1G3, Canada
  • GSK Investigational Site
    London, Ontario N6A 5A5, Canada
  • GSK Investigational Site
    Sudbury, Ontario P3E 5J1, Canada
  • GSK Investigational Site
    Montreal, Quebec H1T 2M4, Canada
  • GSK Investigational Site
    Liberec, 460 63, Czechia
  • GSK Investigational Site
    Louny, 440 01, Czechia
  • GSK Investigational Site
    Most, 434 64, Czechia
  • GSK Investigational Site
    Praha 10, 100 34, Czechia
  • GSK Investigational Site
    Praha 2, 128 08, Czechia
  • GSK Investigational Site
    Praha 4, 142 00, Czechia
  • GSK Investigational Site
    Sokolov, 356 01, Czechia
  • GSK Investigational Site
    Odense C, 5000, Denmark
  • GSK Investigational Site
    Roskilde, DK-4000, Denmark
  • GSK Investigational Site
    Amiens cedex 1, 80054, France
  • GSK Investigational Site
    Bordeaux, 33000, France
  • GSK Investigational Site
    Caen Cedex 9, 14033, France
  • GSK Investigational Site
    Paris Cedex 15, 75743, France
  • GSK Investigational Site
    Mannheim, Baden-Wuerttemberg 68167, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81675, Germany
  • GSK Investigational Site
    Demmin, Mecklenburg-Vorpommern 17109, Germany
  • GSK Investigational Site
    Duesseldorf, Nordrhein-Westfalen 40210, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04129, Germany
  • GSK Investigational Site
    Berlin, 12053, Germany
  • GSK Investigational Site
    Hamburg, 22297, Germany
  • GSK Investigational Site
    Budapest, 1115, Hungary
  • GSK Investigational Site
    Esztergom, 2500, Hungary
  • GSK Investigational Site
    Pécs, 7624, Hungary
  • GSK Investigational Site
    Pécs, 7633, Hungary
  • GSK Investigational Site
    Aichi, 441-8023, Japan
  • GSK Investigational Site
    Ehime, 790-0952, Japan
  • GSK Investigational Site
    Ehime, 790-0962, Japan
  • GSK Investigational Site
    Fukuoka, 803-0844, Japan
  • GSK Investigational Site
    Kyoto, 617-0813, Japan
  • GSK Investigational Site
    Niigata, 940-0053, Japan
  • GSK Investigational Site
    Wakayama, 640-8335, Japan
  • GSK Investigational Site
    Yamagata, 990-0834, Japan
  • GSK Investigational Site
    Anyang-Si Gyeonggi-do, 431-070, Korea, Republic of
  • GSK Investigational Site
    Daegu, 700-721, Korea, Republic of
  • GSK Investigational Site
    Daejeon, 301-721, Korea, Republic of
  • GSK Investigational Site
    Gwangju, 501-757, Korea, Republic of
  • GSK Investigational Site
    Incheon, 405-760, Korea, Republic of
  • GSK Investigational Site
    Seoul, 120-752, Korea, Republic of
  • GSK Investigational Site
    Oslo, 0027, Norway
  • GSK Investigational Site
    Oslo, 0405, Norway
  • GSK Investigational Site
    Stavanger, 4011, Norway
  • GSK Investigational Site
    Trondheim, 7006, Norway
  • GSK Investigational Site
    Tønsberg, 3116, Norway
  • GSK Investigational Site
    Krakow, 31-501, Poland
  • GSK Investigational Site
    Tarnow, 33-100, Poland
  • GSK Investigational Site
    Warszawa, 02-507, Poland
  • GSK Investigational Site
    Zabrze, 41-800, Poland
  • GSK Investigational Site
    Kaluga, 248007, Russian Federation
  • GSK Investigational Site
    Krasnodar, 350029, Russian Federation
  • GSK Investigational Site
    Krasnogorsk, 143400, Russian Federation
  • GSK Investigational Site
    Moscow, 125101, Russian Federation
  • GSK Investigational Site
    Mytischi, 141009, Russian Federation
  • GSK Investigational Site
    Novosibirsk, 630087, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 191104, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 194354, Russian Federation
  • GSK Investigational Site
    Yaroslavl, 150062, Russian Federation
  • GSK Investigational Site
    Alcala de Henares, 28805, Spain
  • GSK Investigational Site
    Alicante, 03010, Spain
  • GSK Investigational Site
    Almería, 04009, Spain
  • GSK Investigational Site
    Badalona, 08916, Spain
  • GSK Investigational Site
    Barcelona, 08907, Spain
  • GSK Investigational Site
    Córdoba, 14004, Spain
  • GSK Investigational Site
    Granada, 18014, Spain
  • GSK Investigational Site
    Madrid, 28007, Spain
  • GSK Investigational Site
    Madrid, 28224, Spain
  • GSK Investigational Site
    San Sebastian de los Reyes, 28702, Spain
  • GSK Investigational Site
    Santander, 39008, Spain
  • GSK Investigational Site
    Santiago de Compostela, 15706, Spain
  • GSK Investigational Site
    Karlstad, SE-651 85, Sweden
  • GSK Investigational Site
    Stockholm, SE-141 86, Sweden
  • GSK Investigational Site
    Uppsala, SE-751 85, Sweden
  • GSK Investigational Site
    Örebro, SE-701 85, Sweden

Showing the first 100 of 107 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 2 years after primary completion. A results delay was requested in Jun 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2013
First posted
Nov 6, 2013
Start
Nov 1, 2013
Primary completionActual
Feb 1, 2015
CompletionActual
Feb 6, 2015
Results delay requested
Jun 11, 2015
Results first posted
Feb 14, 2017
Last update
Jun 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01977482
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 6, 2013
Start date
Nov 1, 2013
Primary completion
Feb 1, 2015
Completion
Feb 6, 2015
Results posted
Feb 14, 2017
Last update
Jun 8, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion